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  Chernotherapy with anticancer agents was tried against total 5 cases of Stage D adenocarcinoma
of the prostate， of which 4 were hormone resistent and 1 had no estrogen therapy due to side effects．
The following results could be obtained．
  1） General therapy was adopted for treating 4 patients with 700 mg to 1，000 mg of endoxan
（EDX） at an interval of 3一一4 weeks on out－patient basis． More or less clinical effects were attained
in all the patients comprising l with 1－B，2with 1．A， and l with G－B according to Karnofskゾs efficacy
evaluation standards．
  2） Combination chemotherapy of EDX， adriamycin （ADM） and FT－207 or cis－platinum， ADM
and EDX was tried to 2 patients， but the therapy could not be continued to the end due to seriously
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      3，治療方法ならびに成績
 使用した制癌剤はEDX，5－FU， FT－207， adriamycin
Internal iliac arterial irlfusion
Therapy A  D  M@     20mg     30mg
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にEDX l g，第3日目にADM 40mg，第8～ll日
目に1日1200mgのFT－207を投与し，症例4
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